Research library / Rapamycin

CC Small or few human trials. Promising, not proven. How we grade →RCT (pilot) · 25 adults aged 70 to 95

A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects

E Kraig, L Linehan, H Liang, T Romo, Q Liu, Y Wu et al. Experimental Gerontology. 2018.

Published Sources checked 1 sourceEverstack research teamHow we work

In plain language
1 mg of rapamycin a day for 8 weeks lowered several red blood cell measures without clinical effects; glucose tolerance, cognition and physical performance did not change.
Limits
Very small and short; 11 on rapamycin analyzed.
Which of our grades it feeds
Source
doi.org/10.1016/j.exger.2017.12.026 · PubMed 29408453 · Free full text

Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.